journal article·2024-02

Microalgal biomass-assisted delivery of probiotics for modulation of gut homeostasis and alleviation of intestinal inflammation

Zi-Yi Han, Cheng Zhang, Jia-Xin An, Ji-Yan Qiao, Xian-Zheng Zhang

Nano Today· Volume 54
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Gut microbiota and health · Cystic Fibrosis Research Advances

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (55)

Show source-provided references
1. Moving from probiotics to precision probiotics10.1038/s41564-020-0721-1 ↗
2. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics10.1038/nmicrobiol.2017.57 ↗
3. The impact of probiotics and prebiotics on the immune system10.1038/nri3312 ↗
4. Pathogen elimination by probiotic Bacillus via signalling interference10.1038/s41586-018-0616-y ↗
5. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa10.1038/nrmicro2690 ↗
6. Probiotics, gut microbiota, and their influence on host health and disease10.1002/mnfr.201600240 ↗
7. Prevention of infections by probiotics10.1263/jbb.100.583 ↗
8. Injectable and self-healing probiotics-loaded hydrogel for promoting superbacteria-infected wound healing10.1021/acsami.1c23713 ↗
9. Probiotics: Preventing antibiotic-associated diarrhea10.1111/j.1744-6155.2010.00231.x ↗
10. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery10.1038/s41467-022-31171-0 ↗
11. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice
12. The role of probiotics in cancer prevention
13. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial10.1038/s41591-022-01694-6 ↗
14. The pros, cons, and many unknowns of probiotics10.1038/s41591-019-0439-x ↗
15. Risk and safety of probiotics10.1093/cid/civ085 ↗
16. Poly-γ-glutamic acid microgel-encapsulated probiotics with gastric acid resistance and smart inflammatory factor targeted delivery performance to ameliorate colitis
17. Spatial control of probiotic bacteria in the gastrointestinal tract assisted by magnetic particles
18. Biomaterials coating for on-demand bacteria delivery: Selective release, adhesion, and detachment10.1016/j.nantod.2021.101291 ↗
19. Decorated bacteria and the application in drug delivery10.1016/j.addr.2022.114443 ↗
20. Surface modifications for improved delivery and function of therapeutic bacteria
21. Layer-by-layer encapsulation of probiotics for delivery to the microbiome10.1002/adma.201603270 ↗
22. Polymerization-mediated multifunctionalization of living cells for enhanced cell-based therapy10.1002/adma.202007379 ↗
23. Biointerfacial self-assembly generates lipid membrane coated bacteria for enhanced oral delivery and treatment10.1038/s41467-019-13727-9 ↗
24. Physiologically inspired mucin coated Escherichia coli Nissle 1917 enhances biotherapy by regulating the pathological microenvironment to improve intestinal colonization10.1021/acsnano.1c09681 ↗
25. Cell-mediated biointerfacial phenolic assembly for probiotic nano encapsulation10.1002/adfm.202200775 ↗
26. Biofilm-inspired encapsulation of probiotics for the treatment of complex infections
27. Nanoencapsulation for probiotic delivery10.1021/acsnano.1c09951 ↗
28. In situ bioorthogonal conjugation of delivered bacteria with gut inhabitants for enhancing probiotics colonization10.1021/acscentsci.2c00533 ↗
29. Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis10.1038/s41565-023-01346-x ↗
30. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease10.1038/s41591-021-01390-x ↗
31. A programmable encapsulation system improves delivery of therapeutic bacteria in mice10.1038/s41587-022-01244-y ↗
32. Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut10.1038/s41467-019-13336-6 ↗
33. Beneficial microorganisms for corals (BMC): Proposed mechanisms for coral health and resilience10.3389/fmicb.2017.00341 ↗
34. Algae-bacteria interactions: Evolution, ecology and emerging applications10.1016/j.biotechadv.2015.12.003 ↗
35. Research on the treatment mechanism of anthraquinone dye wastewater by algal-bacterial symbiotic system10.1016/j.biortech.2022.126691 ↗
36. Spirulina-From growth to nutritional product: A review10.1016/j.tifs.2017.09.010 ↗
37. The antioxidant, immunomodulatory, and anti-inflammatory activities of Spirulina: an overview10.1007/s00204-016-1744-5 ↗
38. Development of spirulina for the manufacture and oral delivery of protein therapeutics10.1038/s41587-022-01249-7 ↗
39. Microalgae-based oral microcarriers for gut microbiota homeostasis and intestinal protection in cancer radiotherapy10.1038/s41467-022-28744-4 ↗
40. Engineered algae: A novel oxygen-generating system for effective treatment of hypoxic cancer10.1126/sciadv.aba5996 ↗
41. Orally deliverable strategy based on microalgal biomass for intestinal disease treatment10.1126/sciadv.abi9265 ↗
42. Integrated cascade catalysis of microalgal bioenzyme and inorganic nanozyme for anti-inflammation therapy10.1039/D2NH00572G ↗
43. Spirulina in health care management10.2174/138920108785915111 ↗
44. Facile fabrication of magnetic microrobots based on spirulina templates for targeted delivery and synergistic chemo-photothermal therapy10.1021/acsami.8b15586 ↗
45. Biomass and nutritive value of Spirulina (Arthrospira fusiformis) cultivated in a cost-effective medium10.1007/s13213-019-01520-4 ↗
46. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation10.3390/nu10080988 ↗
47. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis10.1038/s41563-019-0462-9 ↗
48. Prodrug integrated envelope on probiotics to enhance target therapy for ulcerative colitis
49. pH and reactive oxygen species-sequential responsive nano-in-micro composite for targeted therapy of inflammatory bowel disease10.1002/adfm.201806175 ↗
50. Puerarin inhibits inflammation and oxidative stress in dextran sulfate sodium-induced colitis mice model10.1016/j.biopha.2020.109847 ↗
51. The microbiome and inflammatory bowel disease10.1016/j.jaci.2019.11.003 ↗
52. The Gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease10.3389/fmicb.2018.02247 ↗
53. The gut microbiota in IBD10.1038/nrgastro.2012.152 ↗
54. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD10.1111/apt.13236 ↗
55. Nanoparticle-modified microrobots for in vivo antibiotic delivery to treat acute bacterial pneumonia10.1038/s41563-022-01360-9 ↗